Investing.com - Edgewise Therapeutics (NASDAQ: EWTX) reported fourth quarter EPS of $-0.34, in line with the analyst estimate of $-0.34. Revenue for the quarter came ...

Piper Sandler has maintained a confident stance on Edgewise Therapeutics (NASDAQ: EWTX), reiterating an Overweight rating with a $48.00 price target. The firm's optimism is tied ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Roche Holding AG Akt 1.54% CHF230.28B ...

After hours: January 29 at 4:57:39 PM EST Loading Chart for APGE ...